Bruce Wendel - 16 Nov 2020 Form 4 Insider Report for GT Biopharma, Inc. (GTBP)

Role
Director
Signature
Bruce Wendel
Issuer symbol
GTBP
Transactions as of
16 Nov 2020
Net transactions value
+$26,299
Form type
4
Filing time
07 Oct 2021, 14:47:17 UTC
Previous filing
07 Oct 2021
Next filing
19 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTBP Common Stock Purchase $10,262 +3,268 $3.14* 3,268 16 Nov 2020 Direct
transaction GTBP Common Stock Purchase $12,187 +1,374 +42% $8.87* 4,642 22 Dec 2020 Direct
transaction GTBP Common Stock Purchase $3,850 +441 +9.5% $8.73* 5,083 22 Dec 2020 Direct
transaction GTBP Common Stock Award $0 +347,572 +6838% $0.000000 352,655 16 Feb 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTBP Option to purchase Common Stock Award $0 +50,000 $0.000000 50,000 16 Feb 2021 Common Stock 50,000 $6.33 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of shares of restricted stock ("RSAs"). 1/3rd of the RSAs vest on November 11 2020, 2021 and 2022.
F2 1/3rd of the shares vest on February 16, 2021, 2022, and 2023.